The latest Samsung Bioepis Biosimilar Market Report (Q2 2026) was released yesterday, and it reveals a host of intriguing movements in both price and market share of biosimilar agents. In this post, we’ll look at the oncology category. The movements of one of the most established drug categories—trastuzumab—caught my eye in the newest release of … Continue reading Market Share vs. ASP: Do Oncology Biosimilar Trends Make Sense?
Copy and paste this URL into your WordPress site to embed
Market Share vs. ASP: Do Oncology Biosimilar Trends Make Sense?
The latest Samsung Bioepis Biosimilar Market Report (Q2 2026) was released yesterday, and it reveals a host of intriguing movements in both price and market share of biosimilar agents. In this post, we’ll look at the oncology category. The movements of one of the most established drug categories—trastuzumab—caught my eye in the newest release of … Continue reading Market Share vs. ASP: Do Oncology Biosimilar Trends Make Sense?